ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

Benign transient hyperphosphatasemia in children

Nedeljko Radlović1, Zoran Leković2,3, Vladimir Radlović4, Siniša Dučić2,3, Zoran Golubović2,3, Marija Mladenović, Meho Mahmutović5, Polina Pavičević2,3, Goran Đurićić2, Snežana Petrović-Tepić6

1Serbian Medical Society, Academy of Medical Sciences, Belgrade, Serbia;
2University Children’s Hospital, Belgrade, Serbia;
3University of Belgrade, Faculty of Medicine, Belgrade, Serbia;
4Valjevo Medical Centre, Valjevo, Serbia;
5Novi Pazar General Hospital, Novi Pazar, Serbia;
6University of Banja Luka, Faculty of Medicine, Republic of Srpska, Bosnia and Herzegovina

SUMMARY

Introduction/Objective Benign transient hyperphosphatasemia (BTH) is a pathogenetic insufficiently clear clinical entity that is mostly seen in infants and young children. The objective of this paper is to present our experience regarding the age of occurrence, the conditions of the discovery, and the length of duration of BTH in children.

Methods The study was realized on a sample of 18 children, nine boys and nine girls, aged 10–42 (21.06 ± 9.35) months with BTH. The diagnosis of BTH is based on the absence of bone and hepatobiliary diseases, and its spontaneous disappearance over the course of several months.

Results One patient was in the first year, 13 in the second, three in the third, and one in the fourth. Isolated high activity of serum alkaline phosphatase, which was 2.04–21.9 (8.05 ± 5.31) times above the upper reference value for the corresponding age, was found in 14 cases. The diagnosis of BTH was based on the absence of bone and hepatobiliary diseases, and its spontaneous disappearance over the course of several months.

Conclusion BTH is a harmless biochemical disorder that spontaneously subsides within three months after initial observation. It is found randomly as a routine laboratory finding most often within the treatment of acute gastrointestinal and respiratory infections.

Keywords: benign transient hyperphosphatasemia; diagnostics; children

INTRODUCTION

Benign transient hyperphosphatasemia (BTH) is a complex and pathogenetically vague clinical entity expressed by transiently increased serum activity of alkaline phosphatase (ALP) [1–7]. It occurs in the absence of skeletal, liver, and other diseases characterized by the increase in ALP [2, 3, 5–9]. It is detected by accident either during routine laboratory analyzes or by examining one of the diseases [2, 3, 5–10]. It is most commonly found in children under five years of age, especially in infants, and rarely later [2–12]. Although seldom, BTH also occurs in adults [13]. Return to normal ALP levels usually occurs within four months, and sometimes a little later [4, 9–12]. The most common circumstance of its occurrence are various infections, usually viral, and rarely other pathological conditions [1, 3, 10, 14]. Bearing in mind the absence of any negative consequences, BTH is considered a benign biochemical disorder and does not require extensive investigations nor the use of vitamin D or other therapeutic procedures [3, 4, 8].

We present our experience regarding the age of occurrence, detection conditions, diagnostic mode, and duration of BTH in children.

METHODS

The study included a sample of 18 children, nine boys and nine girls, aged 10–42 (21.06 ± 9.35) months with BTH. The diagnosis of BTH is based on the absence of bone and hepatobiliary diseases, and its spontaneous disappearance over the next few months. The study protocol was approved by the local ethics committee.

Apart from current infections in which isolated elevated serum ALP levels were identified, medical history, clinical findings, and routine laboratory analyzes indicated that the patients were healthy, optimally developed and adequately nourished children.

Bearing in mind the fact that skeletal and hepatobiliary diseases are the most frequent cause of increased serum activity of ALP, initial diagnostic procedures have been primarily targeted in this direction. In this sense, ultrasonographic examination of the abdomen and radiography of the wrist was done in all the patients. A key laboratory parameter for the absence of a hepatobiliary disease as the cause of hyperphosphatemia was the normal serum activity of gamma glutamyl transferase, while the elimination of bone disease was based on
the values of several laboratory parameters, such as normal serum calcium, phosphorus, 25(OH)D, parathyroid hormone, creatinine, as well as blood acid-base status and urinary calcium/creatinine ratio. After skeletal and hepatobiliary disorders were excluded, the follow-up of the patients included a checkup of ALP every two to four weeks, until the normalization of the values.

RESULTS

One patient was in the first year, 13 in the second, three in the third, and one in the fourth.

In all the patients, BTH was detected accidentally within a routine laboratory blood test, in 14 with acute diarrhea and in four with acute rhinopharyngitis, two of which complicated by otitis media. The cause of diarrhea in six cases was rotavirus, in two it was Campylobacter, and in one adenovirus, and otitis media in one case was caused by Streptococcus pneumoniae, while in other etiologic factors of infection it was not identified.

The initial value of serum ALP was 2.04–21.9 (8.05 ± 5.31) times above the upper reference value for the corresponding age, while its spontaneous normalization was registered approximately after one to three months of follow-up – in 10 patients within one month, in four within five months, and in four within three months.

DISCUSSION

ALP is an omnipresent cell membranous zinc-containing metalloenzyme that catalyzes the hydrolysis of phosphate monoesters at basic pH values [15, 16]. According to the origin, human APHs are divided into four isozymes – intestinal, placental, germ cell, and tissue nonspecific or liver/bone/kidney [2, 15, 16]. Except for the bone ALP, which has a role in skeletal mineralization, the exact physiological function of other isoenzymes both in the physiological and pathological conditions is not clear [16–19]. In circulation it is an inactive enzyme. The half-life of the liver isoenzyme in the blood is three days, and of the bone isoenzyme it is one to two days [20, 21]. The serum level of ALP in children is normally two to three times higher than in adults due to physiologically higher osteoblast activity [2]. For the same reason, bone isoenzyme in healthy children contributes by 85% to ALP activity, and liver isoenzyme contributes by only 15% [2]. Due to placental isoenzyme, the serum ALP level is physiologically elevated during pregnancy, while in all other conditions, with the exception of BTH, it represents a significant marker of the presence of various diseases, primarily skeletal and hepatobiliary [3].

BTH represents a harmless biochemical abnormality that spontaneously disappears within a few months [1–9]. It is most commonly found in children under five years of age, usually as an incidental finding during laboratory testing in routine health care, or as part of an evaluation for a specific complaint [2, 3, 5, 10]. When it comes to children, the most common illnesses accompanied by BTH are various infections, usually viral, and rarely other pathological conditions [1–5, 10, 11, 14, 22, 23, 24]. Also, BTH occurs as part of the use of some drugs, such as sulfamethoxazole/trimethoprim, cyclosporine, methotrexate and 6-mercaptopurine, as well as after renal and liver transplantation [25–28]. There are descriptions of rare cases of benign familial hyperphosphatasemia [29, 30].

Our patients demonstrate the classic features of children with BTH. Apart from current infections in which isolated elevation of serum ALP levels were identified, all were healthy, optimally developed and adequately nourished children. They all belonged to the children of the youngest age, of whom 13 were in the second and third year, one in the first, and one in the fourth. Similar to most authors, BTH was found in our patients as an incidental finding during routine laboratory testing as part of an evaluation of intercurrent infections. In 14 of our patients, BTH was identified during acute infectious diarrhea, and in four during acute upper respiratory infection, two of which were complicated by otitis media. The cause of diarrhea in six patients was rotavirus, Campylobacter was the cause in two, and adenovirus in one, while Streptococcus pneumoniae was the cause of otitis media in one patient; in other patients, etiologic factors of infection were not identified. The period of spontaneous normalization of serum ALP activity occurred after 1–3 months, so none of them, except initial exclusion of bone and hepatobiliary disease, required additional examination.

CONCLUSION

BTH represents a harmless biochemical disorder. Its diagnosis is based on the absence of bone and hepatobiliary diseases, and its spontaneous disappearance over the next few months. According to our findings, it occurs in children within the first four years of life as a random finding during a routine laboratory testing as part of evaluation of intercurrent gastrointestinal and respiratory infections. If bone and hepatobiliary disorders are excluded and thereafter a spontaneous fall in the serum ALP activity takes place, no additional examination is required.

Conflict of interest: None declared.
REFERENCES

1. Dori N, Levi L, Stam T, Sukhotnik I, Shaoul R. Transient hyperphosphatasemia in children revisited. Pediatr Int. 2010; 52(6):866–71.
2. Eymann A, Cacchiarelli N, Alonso G, Llera J. Benign transient hyperphosphatasemia of infancy. A common benign scenario, a big concern for a pediatrician. J Pediatr Endocrinol Metab. 2010; 23(9):927–30.
3. D’Alessandro DM. What is the differential diagnosis of hyperphosphatasemia? PediatricEducation.org; May 17, 2010 [cited 2015 May 15]. Available from: http://pediatriceducation.org/2010/05/17/what-is-the-differential-diagnosis-of-hyperphosphatasemia/
4. Shapira M, Shaoul R. An 18-month-old boy with diarrhea and an elevated biochemical parameter. Pediatr Ann. 2015; 44(6):232–4.
5. Kutilek S, Cervickova B, Bebova P, Kmonickova M, Nemec V. Normal bone turnover in transient hyperphosphatasemia. J Clin Res Pediatr Endocrinol. 2012; 4(3):154–6.
6. Bassrawi R, Alsabie N, Alsorani D, Babiker A. Transient hyperphosphatasemia in children. Srp Arh Celok Lek. 2020 Jan-Feb;148(1-2):48-51DOI: https://doi.org/10.2298/SARH180904083R
7. Chesney RW. Hyperphosphatasia. In: Kliegman RM, Stanton BF, St Geme III JW, Schor NF, editors. Nelson Textbook of Pediatrics. 20th ed. Philadelphia: Elsevier; 2016. p. 3394–5.
8. Kutilek S, Cervickova B, Bebova P, Kmonickova M, Nemec V. Normal bone turnover in transient hyperphosphatasemia. J Clin Res Pediatr Endocrinol. 2012; 4(3):154–6.
9. Çakır BC, Kirsaçlioğlu CT, Tartıcı EK, Demirel F. Transient hyperphosphatasemia in children: a prospective study of 43 cases. J Contemp Med. 2017; 7(2):138–42.
10. Chu AS, Rothschild JG. Update on benign transient hyperphosphatasemia. J Pediatr. 2010; 152(6):866–71.
11. Gualco G, Lava SA, Garzoni L, Simonetti GD, Bettinelli A, Milani RW. Alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1993; 31(3):197–293.
12. Teitelbaum JE, Laskowski A, Barrows FP. Benign transient hyperphosphatasemia. J Pediatr. 2010; 157(5):406–9.
13. Jassam NJ, Horner J, Marzo-Ortega H, Sinclair M, Barth JH. Transient rise in alkaline phosphatase activity in adults. BMJ Case Reports. 2009; 2009.
14. Akcaboy M, Zorlu P, Acoglu EA, Acar M, Oguz MM, Senel S. Human Bocavirus infection associated transient benign hyperphosphatasemia in an infant. Indian J Pediatr. 2016; 83(8):902–3.
15. Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1994; 31(3):197–293.
16. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014; 29(3):269–78.
17. Millán JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int. 2016; 98(4):398–416.
18. Millán JL. Alkaline Phosphatases: Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal. 2006; 2(2):335–41.
19. Hoylaerts MF, Van Kerckhovens S, Kiffer-Moreira T, Sheen C, Narisawa S, Millán JL. Functional significance of calcium binding to tissue-nonspecific alkaline phosphatase. PLoS One. 2015; 10(3):e0119874.
20. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172(3):367–79.
21. Sardiwal S, Gardham C, Coleman AE, Stevens PE, Delaney MP, Lamb EJ. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int. 2012; 82(1):100–5.
22. Koike Y, Aoki N. Benign transient hyperphosphatasemia associated with Epstein–Barr virus infection. Pediatr Int. 2013; 55(5):667–8.
23. Suzuki M, Okazaki T, Nagai T, Torô K, Sétonyi P. Viral infection of infants and children with benign transient hyperphosphatasemia. FEMS Immunol Med Microbiol. 2002; 33(3):215–8.
24. Massey GV, Dunn NL, Heckel JL, Chan JC, Russell EC. Benign transient hyperphosphatasemia in children with leukemia and lymphoma. Clin Pediatr (Phila). 1996; 35(10):501–4.
25. Mori T, Tanaka R, Nishida K, Yamamoto N, Hayakawa A, Nishimura N, et al. Transient hyperphosphatasemia in three pediatric patients treated with cyclosporine. Pediatr Int. 2016; 58(5):429–30.
26. Kutilek S, Skálová S, Vethamuthu J, Geier P, Feber J. Transient hyperphosphatasemia in pediatric renal transplant patients – is there a need for concern and when? Pediatr Transplant. 2012; 16(1):ES–9.
27. Arikan C, Arslan MT, Kilic M, Aydogdu S. Transient hyperphosphatasemia after pediatric liver transplantation. Pediatr Int. 2006; 48(4):390–2.
28. Yoshimaru K, Matsuura T, Hayashida M, Kinosita Y, Takahashi Y, Yanagi Y, et al. Transient hyperphosphatasemia after pediatric liver transplantation. Pediatr Int. 2016; 58(7):726–31.
29. Rosalki SB, Foy AF, Dooley JS. Benign familial hyperphosphatasemia as a cause of unexplained increase in plasma alkaline phosphatase activity. J Clin Pathol. 1993; 46(8):738–41.
30. Hoshino T, Kumasaka K, Kawano K, Yamagishi F, Sakai H, Komoda T. A case of benign familial hyperphosphatasemia of intestinal origin. Clin Biochem. 1993; 26(5):421–5.
САЖЕТАК
Увод/Циљ Бенигна пролазна хиперфосфатаземија (БПХФ) представља патогенетски недовољно јасан клинички енти-тет, који се претежно виђа код одојчади и мале деце. Циљ рада је да се изнесу наша искуства везана за узраст јављања, околности откривања и дужину трајања БПХФ код деце.
Методе Рад је реализован на узорку од 18 деце – девет де-чака и девет девојчица, узраста 10–42 (21,06 ± 9,35) месеца са БПХФ. Дијагноза БПХФ је базирана на одсуству коштаних и хепатобилијарних обољења, као и њеном спонтаном иш-чезавању током неколико наредних месеци.
Резултати Једно дете је било у првој години, 13 у другој, три у трећој и једно у четвртој. Изолована висока активност се-румске алкалне фосфатазе, која је била 2,04–21,9 (8,05 ± 5,31) пута изнад горње референтне вредности за одговарајућу старост, код 14 случајева је нађена у оквиру акутне дија-реје и код четири случаја са акутним ринофарингитисом, од чега код два са компликованим отитисним медијем. Узрок дијареје у шест случајева био је ротовирус, у два случаја камилобактерија и у једном случају аденовирус, а узрок отитисног медија у једном случају биле су стрептококс пневмоније, док код осталих етиолошки чинилац инфекције није идентификован. Спонтана нормализација серумске актив-ности алкалне фосфатазе регистровања је између једног и три месеца.
Закључак БПХФ представља безазлен биохемијски поре-мећа који се спонтано повлачи унутар три месеца после иницијалне опсервације. Открива се случајно као рутински лабораторијски налаз најчешће у склопу третмана акутних гастроинтестиналних и респираторних инфекција.
Кључне речи: бенигна пролазна хиперфосфатаземија; дијагностика; деца